Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05811364
Other study ID # VBX 22-06
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 17, 2023
Est. completion date April 30, 2031

Study information

Verified date November 2023
Source W.L.Gore & Associates
Contact Makensley Lordeus
Phone 623-234-5989
Email mlordeus@wlgore.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this prospective, multicenter, randomized, controlled clinical trial is to demonstrate the superiority of the VBX Device for primary patency when compared to bare metal stenting in complex iliac occlusive disease.


Recruitment information / eligibility

Status Recruiting
Enrollment 244
Est. completion date April 30, 2031
Est. primary completion date April 30, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years at time of informed consent signature - Informed Consent Form (ICF) is signed by the subject - Subject can comply with protocol requirements, including follow-up - Patient has symptomatic claudication, rest pain, or minor tissue loss (Rutherford Category 2-5) - Patient has de novo or restenotic lesion(s) found in the common and/or external iliac artery(ies) - Patient has: Unilateral or bilateral single or multiple lesions (>50% stenosis or chronic total occlusion) each between 4 and 11 cm in length - Patient has a target vessel diameter visually estimated to be approximately between 5 mm and 13 mm - Patient has a sufficient (<50% stenotic) common femoral artery and at least one sufficient (<50% stenotic) femoral artery (deep or superficial). - Patient has at least one sufficient (<50% stenotic) infrapopliteal run-off vessel. Exclusion Criteria: - Life expectancy <1 year - Patient is pregnant at time of informed consent. - Patient has a known allergy to stent or stent graft components (including nitinol, stainless steel, or heparin). - Patient has severe chronic renal insufficiency (serum creatinine level > 2.5mg/dL) and not undergoing hemodialysis. - Patient has evidence of a systemic infection. - Patient has a known intolerance to antithrombotic medications that prevent compliance with study or control device Instructions for Use. - Patient has had vascular catheterization of the lower extremities within 30 days of randomization (excluding diagnostic angiograms for the study procedure). - Patient has previous stenting in the iliac arteries. - Patient has previous surgical bypass in the target limb. - Patient is currently participating in another investigative clinical study unless received written approval by the sponsor. - Patient has a lesion requiring drug-coated balloon angioplasty, atherectomy, lithotripsy, or any ablative device to facilitate stent delivery. - Patient has an abdominal aortic artery lesion or aneurysm. - Patient has a lesion that requires stent placement within 2 cm of the inguinal ligament. - Patient has isolated common iliac artery stenosis that can be treated with a single device (i.e., common iliac artery stenosis that does not require kissing stents or extend into the external iliac artery). - Patient has outflow disease that requires concomitant interventions (i.e. common femoral endarterectomy or femoral / tibial revascularization).

Study Design


Intervention

Device:
Stenting of the Common and/or External Iliac Arteries with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis
Treatment of target lesions in the common and/or external iliac arteries by stenting with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis.
Stenting of the Common and/or External Iliac Arteries with Bare Metal Stent
Treatment of target lesions in the common and/or external iliac arteries by stenting with a commercially available bare metal stent that is approved for treatment of the disease.

Locations

Country Name City State
Germany Krankenhaus der Barmherzigen Brüder Regensburg
Netherlands Rijnstate Hospital Arnhem
New Zealand Auckland City Hospital Auckland
United States The University of Texas Southwestern Medical Center Dallas Texas
United States North Suburban Medical Center Denver Colorado
United States Radiology and Imaging Specialists of Lakeland Lakeland Florida
United States Texas Tech University Health Science Center Lubbock Texas
United States University of Pennsylvania Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
W.L.Gore & Associates

Countries where clinical trial is conducted

United States,  Germany,  Netherlands,  New Zealand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Patency Blood flow through the target lesion (no evidence of binary restenosis >50% or occlusion) without a Target Lesion Revascularization (TLR). 1 year
Secondary Technical success Deployment of device with < 30% residual stenosis on final angiography. at the procedure
Secondary Acute procedural success Binary assessment based on technical success and freedom from device or procedure-related serious adverse events (SAE) requiring intervention. at the procedure
Secondary Clinical success Improvement from baseline of at least 1 Rutherford Category and freedom from device or procedure-related SAE requiring intervention. Through 1 month
Secondary Hemodynamic Status Change in Ankle-brachial index (ABI)/toe-brachial index (TBI) as compared to baseline Through 5 years
Secondary Change in EQ-5D-5L Change in EQ-5D-5L responses as compared to baseline. The EQ-5D-5L Questionnaire measures quality of life (QoL) over 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is measured over five levels from no problems to extreme problems. Scored on a 0 to 100 scale with 0 as the worst possible health and 100 is the best possible health. Through 5 years
Secondary Change in WIQ Change in Walking Impairment Questionnaire (WIQ) responses as compared to baseline. The WIQ is a validated QoL measurement of walking abilities over 3 dimensions: distance, speed, and stair-climbing. Scored on a 0 to 100 scale with 0 as no degree of difficulty and 100 is the highest degree of difficulty. Through 5 years
Secondary Primary patency Blood flow through the target lesion (no evidence of binary restenosis >50% or occlusion) without a Target Lesion Revascularization (TLR). Through 5 years
Secondary Freedom from binary restenosis Freedom from binary restenosis. binary restenosis defined as evidence of >50% restenosis or occlusion of the target lesion(s) based on core lab adjudicated duplex ultrasound or angiography Through 5 years
Secondary Primary assisted patency Blood flow maintained (no evidence of occlusion) through the target lesion with or without a Target Lesion Revascularization (TLR). Through 5 years
Secondary Secondary patency Blood flow through the target lesion with or without a Target Lesion Revascularization (TLR). Through 5 years
Secondary Freedom from target lesion revascularization Freedom from target lesion revascularization (TLR). TLR defined as endovascular or surgical intervention performed on the target lesion(s). Through 5 years
Secondary Cumulative reintervention rate Rate of first and recurrent Target Lesion Revascularization (TLR). Through 5 years
Secondary Freedom from clinically driven target lesion revascularization Freedom from clinically driven target lesion revascularization. Endovascular or surgical intervention performed on the target lesion(s) in response to recurrent symptoms (increase = 1 Rutherford Category). Through 5 years
Secondary Amputation-free survival Binary assessment based on freedom from major amputation (target limb, amputation above the metatarsals) and all-cause mortality Through 5 years
Secondary Survival Freedom from all-cause mortality Through 5 years
Secondary Change in Rutherford Category Change in Rutherford Category as compared to baseline. Scaled from 0 to 6, with 0 as asymptotic and 6 as major tissue loss, extending above the transmetatarsal (TM) level, functional foot no longer salvageable. Through 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Recruiting NCT05961943 - RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients N/A
Recruiting NCT06047002 - Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Completed NCT03185052 - Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach N/A
Recruiting NCT05992896 - A Study of Loco-Regional Liposomal Bupivacaine Injection Phase 4
Completed NCT04635501 - AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Withdrawn NCT03994185 - The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease N/A
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Recruiting NCT02915796 - Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty Phase 1
Active, not recruiting NCT02900924 - Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
Completed NCT02901847 - To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities. N/A
Not yet recruiting NCT02455726 - Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease N/A
Not yet recruiting NCT02387450 - Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication Phase 2/Phase 3
Withdrawn NCT02126540 - Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries N/A
Completed NCT02384980 - Saving Life and Limb: FES for the Elderly With PAD Phase 1